Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;27(8):720-724.
doi: 10.5863/1551-6776-27.8.720. Epub 2022 Nov 17.

A Preliminary Assessment of the Effects of Pharmacist-Driven Methadone Stewardship for the Treatment of Neonatal Abstinence Syndrome at a Tertiary Children's Hospital

Gregorey Celestin  1   2 , Meagan Balding  1   3 , Jenna L Para  1 , Aubrey Utley  1   4 , Brittany Powers Shaddix  1
Affiliations

A Preliminary Assessment of the Effects of Pharmacist-Driven Methadone Stewardship for the Treatment of Neonatal Abstinence Syndrome at a Tertiary Children's Hospital

Gregorey Celestin et al. J Pediatr Pharmacol Ther. 2022.

Abstract

Objective: Lack of a standardized opioid wean guideline for the treatment of neonatal abstinence syndrome (NAS) has the potential to increase the length of the wean and subsequently the length of stay for neonates in the neonatal intensive care unit (NICU). The purpose of this study was to assess the effect of a pharmacist-driven methadone stewardship program for NAS treatment.

Methods: The NAS stewardship program consisted of provider, pharmacist, and nursing education, a pharmacy surveillance system rule, and an updated clinical practice guideline. The pre- and post-intervention period were defined as patients admitted to the NICU from July 2019-October 2019 and August 2020-November 2020, respectively. The primary objective was to assess the effect of the stewardship program on the duration of opioid treatment in days. Secondary outcomes included number of dose titrations and length of hospital stay.

Results: A total of 21 patients were included in this study. Neonates treated following the adoption of the stewardship program (n = 8) experienced a 34% decreased median duration of treatment (29 days vs 19 days; p = 0.84). Secondary endpoints of median number of titrations and length of stay were decreased by 15% (1.5 titrations; p = 0.52) and 24% (8 days; p = 0.85), respectively, leading to an average cost savings of $60,020 per patient.

Conclusions: Implementation of a standardized stewardship guideline for treatment of NAS resulted in a favorable decrease in all considered endpoints. Implications of the study further support the need for more evidence-based standardized guidelines for optimal treatment of patients with NAS.

Keywords: methadone; neonatal abstinence syndrome; neonatal intensive care unit; neonatal opioid withdrawal syndrome; pharmacologic treatment; weaning.

PubMed Disclaimer

Conflict of interest statement

Disclosures. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Figures

Figure 1.
Figure 1.
Implemented guideline developed for Studer Family Children's Hospital.
Figure 2.
Figure 2.
Pre- and post-interventional endpoints.Error bars in graph denote median absolute deviation. Number of titrations was defined as any adjustment in medication dose or frequency. Length of stay refers to length of total hospital admission.
See this image and copyright information in PMC

References

    1. Winkelman TN, Villapiano N, Kozhimannil KB et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004–2014. Pediatrics . 2018;141(4):e20173520. - PMC - PubMed
    1. Loudin S, Werthammer J, Prunty L et al. A management strategy that reduces NICU admissions and decreases charges from the front line of the neonatal abstinence syndrome epidemic. J Perinatol . 2017;37(10):1108–1111. - PMC - PubMed
    1. Burns L, Mattick RP. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev . 2007;26(5):487–492. - PubMed
    1. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson N, editor. Current Therapy in NeonatalPerinatal Medicine . 2nd ed. BC Decker; 1990. pp. 262–270.
    1. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics . 2012;129(2):e540–e560. - PubMed

LinkOut - more resources